Retatrutide (10mg)
Retatrutide (10mg)
Retatrutide (10mg)
The most powerful weight loss peptide ever studied, activating three metabolic pathways simultaneously. Clinical trials show jaw-dropping results: up to 24% total body weight loss in 48 weeks, with participants losing an average of 58 pounds and experiencing significant improvements in metabolic markers.
The most powerful weight loss peptide ever studied, activating three metabolic pathways simultaneously. Clinical trials show jaw-dropping results: up to 24% total body weight loss in 48 weeks, with participants losing an average of 58 pounds and experiencing significant improvements in metabolic markers.
2,900,000 IDR
2,900,000 IDR
Lab Reports & COA's
Lab Reports & COA's
Purity
Passed
Purity
Passed
Purity
Passed
Endotoxins
Passed
Endotoxins
Passed
Endotoxins
Passed
Heavy Metals
Passed
Heavy Metals
Passed
Heavy Metals
Passed
Sterility
Passed
Sterility
Passed
Sterility
Passed
How should I store this peptide?
How should I store this peptide?
How should I store this peptide?
What purity are your peptides?
What purity are your peptides?
What purity are your peptides?
Research Use Only [Disclaimer]
Research Use Only [Disclaimer]
Research Use Only [Disclaimer]
Same-day shipping
Local orders are delivered same-day
Same-day shipping
Local orders are delivered same-day
Same-day shipping
Local orders are delivered same-day
Free deliveries and returns worldwide
We deliver across the world for free
Free deliveries and returns worldwide
We deliver across the world for free
Free deliveries and returns worldwide
We deliver across the world for free
Guaranteed returns within first two weeks
Return us desired item within two weeks
Guaranteed returns within first two weeks
Return us desired item within two weeks
Guaranteed returns within first two weeks
Return us desired item within two weeks
Overview
Lab Reports
Storage
Overview
What Retatrutide Is & How It Works
Retatrutide (LY‑3437943) is an investigational triple‑receptor agonist peptide engineered to simultaneously activate three key metabolic hormone receptors: GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and the glucagon receptor. This multi‑pronged mechanism blends appetite suppression and satiety signaling with enhanced insulin sensitivity and increased energy expenditure via fat mobilization, creating a broader metabolic effect than single‑ or dual‑agonist compounds.
Clinical Research Highlights & Keys Stats
In mid‑stage clinical studies involving adults with overweight or obesity, Retatrutide produced dose‑dependent and substantial reductions in body weight. Phase 2 data showed participants lost up to ~24.2% of body weight over 48 weeks, outperforming many existing metabolic agents in similar populations.:contentReference[oaicite:1]{index=1} A recent systematic review reported statistically significant mean weight reductions compared to placebo, with a greater likelihood of achieving ≥10% and ≥15% weight loss in active groups.:contentReference[oaicite:2]{index=2} Additionally, improvements in insulin sensitivity, glycemic control, and reductions in total body fat mass have been seen alongside favorable shifts in metabolic markers in trial settings.
Metabolic & Research‑Relevant Outcomes
The triple receptor engagement helps dampen appetite and hunger cues, promotes glucose‑dependent insulin activity, and supports fat oxidation and energy use rather than storage. This combination shows promise not only for weight regulation but also for broader cardiometabolic health outcomes — such as reductions in liver fat and improvements in lipid profiles — in research models.:contentReference[oaicite:4]{index=4} Side effects observed in trials have primarily been gastrointestinal in nature (e.g., nausea, diarrhea), consistent with other incretin‑based therapies, and overall safety continues to be evaluated as the compound progresses through later phases of clinical research.
Overview
Lab Reports
Storage
Overview
What Retatrutide Is & How It Works
Retatrutide (LY‑3437943) is an investigational triple‑receptor agonist peptide engineered to simultaneously activate three key metabolic hormone receptors: GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and the glucagon receptor. This multi‑pronged mechanism blends appetite suppression and satiety signaling with enhanced insulin sensitivity and increased energy expenditure via fat mobilization, creating a broader metabolic effect than single‑ or dual‑agonist compounds.
Clinical Research Highlights & Keys Stats
In mid‑stage clinical studies involving adults with overweight or obesity, Retatrutide produced dose‑dependent and substantial reductions in body weight. Phase 2 data showed participants lost up to ~24.2% of body weight over 48 weeks, outperforming many existing metabolic agents in similar populations.:contentReference[oaicite:1]{index=1} A recent systematic review reported statistically significant mean weight reductions compared to placebo, with a greater likelihood of achieving ≥10% and ≥15% weight loss in active groups.:contentReference[oaicite:2]{index=2} Additionally, improvements in insulin sensitivity, glycemic control, and reductions in total body fat mass have been seen alongside favorable shifts in metabolic markers in trial settings.
Metabolic & Research‑Relevant Outcomes
The triple receptor engagement helps dampen appetite and hunger cues, promotes glucose‑dependent insulin activity, and supports fat oxidation and energy use rather than storage. This combination shows promise not only for weight regulation but also for broader cardiometabolic health outcomes — such as reductions in liver fat and improvements in lipid profiles — in research models.:contentReference[oaicite:4]{index=4} Side effects observed in trials have primarily been gastrointestinal in nature (e.g., nausea, diarrhea), consistent with other incretin‑based therapies, and overall safety continues to be evaluated as the compound progresses through later phases of clinical research.
Overview
Lab Reports
Storage
Overview
What Retatrutide Is & How It Works
Retatrutide (LY‑3437943) is an investigational triple‑receptor agonist peptide engineered to simultaneously activate three key metabolic hormone receptors: GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and the glucagon receptor. This multi‑pronged mechanism blends appetite suppression and satiety signaling with enhanced insulin sensitivity and increased energy expenditure via fat mobilization, creating a broader metabolic effect than single‑ or dual‑agonist compounds.
Clinical Research Highlights & Keys Stats
In mid‑stage clinical studies involving adults with overweight or obesity, Retatrutide produced dose‑dependent and substantial reductions in body weight. Phase 2 data showed participants lost up to ~24.2% of body weight over 48 weeks, outperforming many existing metabolic agents in similar populations.:contentReference[oaicite:1]{index=1} A recent systematic review reported statistically significant mean weight reductions compared to placebo, with a greater likelihood of achieving ≥10% and ≥15% weight loss in active groups.:contentReference[oaicite:2]{index=2} Additionally, improvements in insulin sensitivity, glycemic control, and reductions in total body fat mass have been seen alongside favorable shifts in metabolic markers in trial settings.
Metabolic & Research‑Relevant Outcomes
The triple receptor engagement helps dampen appetite and hunger cues, promotes glucose‑dependent insulin activity, and supports fat oxidation and energy use rather than storage. This combination shows promise not only for weight regulation but also for broader cardiometabolic health outcomes — such as reductions in liver fat and improvements in lipid profiles — in research models.:contentReference[oaicite:4]{index=4} Side effects observed in trials have primarily been gastrointestinal in nature (e.g., nausea, diarrhea), consistent with other incretin‑based therapies, and overall safety continues to be evaluated as the compound progresses through later phases of clinical research.
PEPTIDES
PEPTIDES
You Might also like
You Might also like
Add these popular peptides to your order now
Add these popular peptides to your order now
Best Seller
Weight Loss
Retatrutide
The most powerful weight loss peptide studied, with clinical trials showing up to 24% body weight reduction in 48 weeks.
Best Seller
Weight Loss / Muscle
Tesamorelin
A GHRH analogue clinically proven to reduce visceral belly fat by 15-18% over 26 weeks.
Best Seller
ENERGY
MOTS-C
A mitochondrial peptide that enhances glucose metabolism by 15-25% and boosts endurance capacity by up to 65%.
Best Seller
RECOVERY
BPC 157
The "wolverine peptide" demonstrating 50-70% accelerated healing in tendon, muscle, and ligament injury models.
Best Seller
RECOVERY
TB 500
A tissue repair peptide demonstrating 40-60% faster recovery times in injury models through enhanced cell migration and healing.
Best Seller
SKIN
GHK CU
A copper peptide complex that increases collagen synthesis by up to 70%, promoting skin firmness and tissue regeneration.
Best Seller
Weight Loss
Retatrutide
The most powerful weight loss peptide studied, with clinical trials showing up to 24% body weight reduction in 48 weeks.
Best Seller
Weight Loss / Muscle
Tesamorelin
A GHRH analogue clinically proven to reduce visceral belly fat by 15-18% over 26 weeks.
Best Seller
ENERGY
MOTS-C
A mitochondrial peptide that enhances glucose metabolism by 15-25% and boosts endurance capacity by up to 65%.
Best Seller
RECOVERY
BPC 157
The "wolverine peptide" demonstrating 50-70% accelerated healing in tendon, muscle, and ligament injury models.
Best Seller
RECOVERY
TB 500
A tissue repair peptide demonstrating 40-60% faster recovery times in injury models through enhanced cell migration and healing.
Best Seller
SKIN
GHK CU
A copper peptide complex that increases collagen synthesis by up to 70%, promoting skin firmness and tissue regeneration.
Best Seller
Weight Loss
Retatrutide
The most powerful weight loss peptide studied, with clinical trials showing up to 24% body weight reduction in 48 weeks.
Best Seller
Weight Loss / Muscle
Tesamorelin
A GHRH analogue clinically proven to reduce visceral belly fat by 15-18% over 26 weeks.
Best Seller
ENERGY
MOTS-C
A mitochondrial peptide that enhances glucose metabolism by 15-25% and boosts endurance capacity by up to 65%.
Best Seller
RECOVERY
BPC 157
The "wolverine peptide" demonstrating 50-70% accelerated healing in tendon, muscle, and ligament injury models.
Best Seller
RECOVERY
TB 500
A tissue repair peptide demonstrating 40-60% faster recovery times in injury models through enhanced cell migration and healing.
Best Seller
SKIN
GHK CU
A copper peptide complex that increases collagen synthesis by up to 70%, promoting skin firmness and tissue regeneration.
FAQ
FAQ